Faustman’s team is preparing for a 5-year, 150-person Phase 2 trial to investigate the potential for repeat BCG vaccination to improve type 1 diabetes in adults with existing disease. According to data from a recent Phase 1 trial directed by the Massachusetts General Hospital Immunobiology Laboratory, the vaccine bacillus Calmette-Guérin (BCG) may have the potential to reverse type 1 diabetes.

Bron: Monthly Prescribing Reference (MPR): Drug News | lees verder..